Neil Mundi, Stephenie D Prokopec, Farhad Ghasemi, Andrew Warner, Krupal Patel, Danielle MacNeil, Christopher Howlett, William Stecho, Paul Plantinga, Nicole Pinto, Kara M Ruicci, Mohammed Imran Khan, Myung Woul Han, John Yoo, Kevin Fung, Axel Sahovaler, David A Palma, Eric Winquist, Joe S Mymryk, John W Barrett, Paul C Boutros, Anthony C Nichols
{"title":"Genomic and human papillomavirus profiling of an oral cancer cohort identifies TP53 as a predictor of overall survival.","authors":"Neil Mundi, Stephenie D Prokopec, Farhad Ghasemi, Andrew Warner, Krupal Patel, Danielle MacNeil, Christopher Howlett, William Stecho, Paul Plantinga, Nicole Pinto, Kara M Ruicci, Mohammed Imran Khan, Myung Woul Han, John Yoo, Kevin Fung, Axel Sahovaler, David A Palma, Eric Winquist, Joe S Mymryk, John W Barrett, Paul C Boutros, Anthony C Nichols","doi":"10.1186/s41199-019-0045-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The genomic landscape of head and neck cancer has been reported through The Cancer Genome Atlas project. We attempt to determine if high-risk human papillomavirus (HPV) or frequently mutated genes are correlated with survival in an oral cancer cohort.</p><p><strong>Methods: </strong>Patient demographic data along with data from final pathology was collected. Tumor DNA was analyzed using a custom Illumina targeted sequencing panel. Five high-risk HPV types were tested by qPCR. Statistical analyses were used to identify associations between patient outcome and mutational status.</p><p><strong>Results: </strong>High-risk HPV types were identified in 7% of cases; HPV status was not associated with survival. Mutations were identified in TP53, TERT promoter, & PIK3CA. Mutations in TP53 were significantly associated with poorer overall survival on multi-variate analysis (<i>p</i> = 0.03).</p><p><strong>Conclusions: </strong>Mutations in TP53 were associated with poor patient survival. Expanding our sample size may identify further predictors of outcome to direct customized cancer care.</p>","PeriodicalId":72518,"journal":{"name":"Cancers of the head & neck","volume":" ","pages":"5"},"PeriodicalIF":0.0000,"publicationDate":"2019-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s41199-019-0045-0","citationCount":"11","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancers of the head & neck","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s41199-019-0045-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 11
Abstract
Background: The genomic landscape of head and neck cancer has been reported through The Cancer Genome Atlas project. We attempt to determine if high-risk human papillomavirus (HPV) or frequently mutated genes are correlated with survival in an oral cancer cohort.
Methods: Patient demographic data along with data from final pathology was collected. Tumor DNA was analyzed using a custom Illumina targeted sequencing panel. Five high-risk HPV types were tested by qPCR. Statistical analyses were used to identify associations between patient outcome and mutational status.
Results: High-risk HPV types were identified in 7% of cases; HPV status was not associated with survival. Mutations were identified in TP53, TERT promoter, & PIK3CA. Mutations in TP53 were significantly associated with poorer overall survival on multi-variate analysis (p = 0.03).
Conclusions: Mutations in TP53 were associated with poor patient survival. Expanding our sample size may identify further predictors of outcome to direct customized cancer care.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
